Efdamrofusp alfa
Modify Date: 2024-09-23 17:36:46
Efdamrofusp alfa structure
|
Common Name | Efdamrofusp alfa | ||
|---|---|---|---|---|
| CAS Number | 2375661-82-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Efdamrofusp alfaEfdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1]. |
| Name | Efdamrofusp alfa |
|---|
| Description | Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Efdamrofusp alfa（0.135 mg/mL；0、6、12 或 24 小时）抑制内皮细胞迁移和管形成[1]。 Efdamrofusp alfa (0-1000 μg/mL) 在体外抑制补体激活[1]。 Cell Migration Assay [1] Cell Line: Human primary umbilical vein endothelial cell (HUVEC) Concentration: 0.135 mg/mL Incubation Time: 0, 6, 12, or 24 h Result: Showed a 20.91% reduction in migration. |
| In Vivo | Efdamrofusp alfa（13.5 μg；3 天）在激光诱导的 CNV 小鼠模型中抑制补体系统的激活[1]。 Efdamrofusp alfa（1.35 mg；单次玻璃体内注射）在非人灵长类动物激光诱导的 CNV 模型中显示出良好的安全性和抗血管生成功效[1]。 Animal Model: C57BL/6J mice[1] Dosage: 13.5 μg; 13.0 μg Administration: 3 days; 7days Result: Significantly reduced C3d deposition. Reduced vascular leakage at 7 days after laser-induced injury. Significantly suppressed CNV formation 7 days after laser-induced injury. Reduced the concentrations of vitreous VEGF-A. Animal Model: Rhesus monkeys[1] Dosage: 1.35 mg Administration: Single intravitreal injection Result: Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days. |
| References |
| No Any Chemical & Physical Properties |